Roche modernizes breast cancer diagnostics with Azure-based AI
Roche has deployed artificial intelligence solutions such as uPath Ki-67, ER, and PR digital pathology algorithms to automate tumor marker analyses. Integrated with Roche's uPath NAVIFY platform, these tools enhance diagnostic precision while reducing manual workload for breast cancer pathologists.
- Organization
- Roche
- Industry
- Healthcare
- Location
- United States
- Published
- December 2021
Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks
- Customer
- Roche
- Provider
- Microsoft
- Maturity
- Production
- Linked source
- PR Newswire
Roche has deployed artificial intelligence solutions such as uPath Ki-67, ER, and PR digital pathology algorithms to automate tumor marker analyses
Primary read
Use case focus
Showing 2 of 2
- 1AI-enhanced pathology analysis
- 2Cancer diagnostic automation
- Integration of AI-based uPath Ki-67, ER, and PR algorithms
- Utilization of Azure-based NAVIFY Digital Pathology platform
- Deep learning for analyzing whole-slide imaging
- Faster tumor marker analysis
- Enhanced pathologist confidence due to AI integration
Architecture
Pathology imaging is analyzed using Azure AI and deep learning models via Roche's uPath NAVIFY platform.
Sources & evidence1
- Customer explicitly identified
- Independent source available
- Recent evidence check available
- Last evidence check: Jul 22, 2026.
The same organization appears in newer AI deployment evidence.
- Same organization re-documented as recently as 2025.
- Cited source last checked Jun 12, 2026 — ok (0/1 broken).
Measures whether this deployment's public evidence persists — not whether the system is still in production.
AI-generated summary. Verify important details with the linked sources before relying on this case.
Explore related AI use cases
Was this useful?
Community
Comments
No published comments yet.